Benidipine

Benidipine, supplied as benidipine hydrochloride, is a calcium channel blocker of the dihydropyridine class developed in Japan and used to treat hypertension and angina pectoris ^[1]. It was patented in 1981 and approved for medical use in 1991, and it is sold mainly in Japan and some neighboring markets under the brand name Coniel ^[1]. It is taken once daily and is regarded as a long-acting agent ^[1].

What distinguishes benidipine from ordinary calcium channel blockers is the breadth of channels it blocks. Most dihydropyridines act mainly on the L-type calcium channel, but benidipine inhibits the L-, N-, and T-type channels together, a so-called triple blockade ^[1]. It also has a distinctive membrane approach: the drug partitions into the cell membrane and dissociates from its target only slowly, which helps explain its long duration of action ^[1]. Beyond calcium channels, benidipine has been found to block the mineralocorticoid receptor, the receptor for the hormone aldosterone, an effect that is separate from its action on calcium channels ^[2].

These mechanisms give benidipine a range of effects on top of lowering blood pressure. It has relatively high selectivity for blood vessels and has been reported to protect the lining of blood vessels, enhance the production of nitric oxide, and act as an antioxidant, contributing to cardioprotective effects in patients with ischemic heart disease, and it has performed well in vasospastic angina ^[1]. Its kidney effects have drawn particular attention: by dilating both the incoming and outgoing arterioles of the kidney's filtering units, the L-, N-, and T-type blockade lowers pressure inside the glomerulus and reduces protein leakage into the urine, a renoprotective pattern seen in hypertensive patients including those with diabetes ^[3][4]. The blockade of the mineralocorticoid receptor and of T-type channels is thought to add anti-inflammatory and tissue-protective benefits independent of blood-pressure control ^[2][4].

Benidipine has been on the Japanese market for decades and is considered a well-established drug with few severe side effects; as a long-acting once-daily dihydropyridine, it shares the general profile of its class ^[1]. It is a prescription medicine and is not widely marketed in Western countries ^[1]. Like other dihydropyridine calcium channel blockers, it can cause the class-typical effects associated with blood-vessel dilation ^[1].

Benidipine is a prescription medicine. The most common side effects come from vasodilation and include ankle or leg swelling, facial flushing, headache, dizziness, palpitations, and sometimes constipation. It should be avoided in cardiogenic shock and used cautiously in severe aortic stenosis or advanced heart failure. Because it is broken down by the liver enzyme CYP3A4, grapefruit juice and strong CYP3A4 inhibitors can raise its levels and deepen the blood pressure drop; combining it with other blood pressure drugs adds to that effect. It is not marketed in the United States.

Benidipine was developed by the Japanese pharmaceutical company Kyowa Hakko Kogyo and introduced in Japan in 1991 under the brand name Coniel for the treatment of hypertension and angina. It belongs to the dihydropyridine class of calcium channel blockers but was distinguished early on by its ability to block three types of calcium channel, the L-, N-, and T-types, rather than the L-type alone. Researchers also characterized its membrane approach, in which the drug embeds in the cell membrane and dissociates slowly from its binding site, giving it a long duration of action suitable for once-daily dosing. It has remained used chiefly in Japan and parts of Asia and is not widely marketed in Western countries.

Benidipine enjoys a solid reputation in Japan and across East Asia as a long-acting antihypertensive with an unusually broad calcium-channel profile. It is particularly esteemed for evidence suggesting benefits beyond blood-pressure lowering, including protection of the kidneys through reduction of proteinuria and favorable effects on cardiac and vascular tissue, which some clinicians attribute to its triple-channel blockade and its action on the mineralocorticoid receptor. Nephrologists have taken interest in its ability to dilate both the afferent and efferent arterioles of the glomerulus, a property thought to ease pressure inside the kidney's filtering units. While less familiar in the West, it is well regarded within the markets where it is used, with a generally smooth once-daily profile.